Jessica A Meisner, MD, MS, MSHP
Assistant Professor of Clinical Medicine (Infectious Diseases)
Department: Medicine
Contact information
Hospital of the University of Pennsylvania, 3400 Spruce Street
Philadelphia, PA 19104
Philadelphia, PA 19104
Education:
Program (War Studies)
King's College of London, London, United Kingdom, 2006.
BA (Biological Sciences)
University of Southern California, Los Angeles, CA, 2007.
BA (International Relations)
University of Southern California, Los Angeles, CA, 2007.
MS (Biohazardous Threat Agents and Emerging Infectious Diseases)
Georgetown University, Washington, DC, 2008.
MD
Drexel University, College of Medicine, Philadelphia, PA, 2013.
Certificat (Global Health Delivery Intensive Certificate)
Harvard School of Public Health, Boston MA, 2014.
MSHP (Healthcare Quality and Safety concentration)
University of Pennsylvania, Philadelphia, PA, 2019.
Permanent linkProgram (War Studies)
King's College of London, London, United Kingdom, 2006.
BA (Biological Sciences)
University of Southern California, Los Angeles, CA, 2007.
BA (International Relations)
University of Southern California, Los Angeles, CA, 2007.
MS (Biohazardous Threat Agents and Emerging Infectious Diseases)
Georgetown University, Washington, DC, 2008.
MD
Drexel University, College of Medicine, Philadelphia, PA, 2013.
Certificat (Global Health Delivery Intensive Certificate)
Harvard School of Public Health, Boston MA, 2014.
MSHP (Healthcare Quality and Safety concentration)
University of Pennsylvania, Philadelphia, PA, 2019.
Description of Clinical Expertise
Focus on infections due to substance use, HIV, endocarditis, and opioid use disorderDescription of Research Expertise
Improving care for under-served populations and issues related to quality of care for HIV positive patients and patients with infections secondary to substance use.Selected Publications
Kelly PJA, Jessop AB, Scialanca M, Singley K, Luck CC, Hoadley A, Meisner J, Bass SB.: Psychosocial Impact of Suspected Xylazine-Associated Skin Wounds Among People Using Fentanyl, Philadelphia, 2022 to 2023. Subst Use Addctn J Oct 2024.Amanda Perez, Shane Nieves, Jessica Meisner,: Outcomes of LA-ART at a syringe exchange. Open Forum Infectious Diseases 2024.
Nicole Loeven, Eric Altneu, Virginie Halpern-Cohen, Kelly Dyer, Kaede Sullivan, Shara Epstein, Daniel Teixera da Silva, Jessica Meisner, Sara Schultz: Increase in iGAS seen at two urban quarternary care centers in Philadelphia: Association with PWID and the unstably housed. IDWeek2023 October 2023 Notes: Poster Presentation.
Kruti J. Yagnik, Jessica A. Meisner: Laboratory Testing Strategies, Detection and Diagnosis In Fundamentals of HIV Medicine 2023 Edition. AAHIVM, W David Hardy Oxford University Press, Chapter 8: 71-77, September 2023.
N. Loeven, K. Dyer, V. Halpern-Cohen, C. Comar, J. Meisner, L. Glaser;: Macrolide and Lincosamide Susceptibility Profiles and Use of Clindamycin for iGAS in One Hosp. in Philadelphia, 2018 - 2022. American Society of Microbiology June 2023 Notes: Poster Presentation.
Zwiebel S, Meisner J, Lowenstein M: National Trends in Medical and Surgical Decision-Making for Recurrent Injection Drug Use-Related Infective Endocarditis: A Survey. J Acad Consult Liaison Psychiatr 64(1): 96-98, January 2023.
Richard Lueking, Wenjing Wei, Norman S. Mang, Jessica K. Ortwine, Jessica Meisner: Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital. Microbiology Spectrum. ASM Journals, 11(1): e0238522. December 2022.
Jain MK, De Lemos JA, McGuire DK, Ayers C, Eitson JL, Sanchez CL, Kamel D, Meisner JA, Thomas EV, Hegde AA, Mocherla S, Strebe JK, Li X, Williams NS, Xing C, Ahmed MS, Wang P, Sadek HA, Schoggins JW.: Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial. Front Pharmacol 13(1): 1020123, September 2022.
Kruti Yagnik, Jessica Meisner: Laboratory Detection Strategies: Diagnostics and Diagnosis, In: Fundamentals of HIV Medicine 2022 Edition. AAHIVM, W David Hardy Oxford University Press, September 2022.
Kalil, A. C., Mehta, A. K., Patterson, T. F., Erdmann, N., Gomez, C. A., Jain, M. K., ... & Colombo, R. E. : Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine 9(12): 1365-1376, December 2021.